Eliaz Therapeutics Reports Positive Findings on XGAL-3 for Sepsis Treatment
Eliaz Therapeutics announced a study published in MedComm showing that its XGAL-3 platform, which selectively removes Galectin-3 from the blood, demonstrated improved survival rates and physiological outcomes in sepsis models. The findings support further clinical development of this novel medical device.
Topics: Galectin-3 removal preclinical studies sepsis XGAL-3 platform